Literature DB >> 34629182

Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort.

Matthew B Clements1, Thomas M Atkinson2, Guido M Dalbagni1, Yuelin Li2, Andrew J Vickers3, Harry W Herr1, S Machele Donat1, Jaspreet S Sandhu1, Daniel S Sjoberg3, Amy L Tin3, Bruce D Rapkin4, Bernard H Bochner5.   

Abstract

BACKGROUND: Radical cystectomy (RC) has the potential for profound changes to health-related quality of life (HRQOL).
OBJECTIVE: To evaluate a broad range of HRQOL outcomes in a large RC cohort. DESIGN, SETTING, AND PARTICIPANTS: A single-center prospective study enrolled RC patients from 2008 to 2014. We collected 14 separate patient-reported outcome measures at the presurgical visit and at 3, 6, 12, 18, and 24 mo after RC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: To visualize the patterns of recovery over time across domains, we used generalized estimating equations (GEEs) with nonlinear terms. Given substantial differences in patient selection for the type of urinary diversion, we separately modeled longitudinal HRQOL within conduit and continent diversion groups. The mean pre-RC scores were compared to illustrate the baseline HRQOL differences between diversion groups. RESULTS AND LIMITATIONS: The analyzed cohort included 411 patients (n = 205 ileal conduit, n = 206 continent diversion). At baseline, patients receiving continent diversion reported better mean physical (p < 0.001), urinary (p = 0.006), and sexual function (p < 0.001), but lower social function (p = 0.015). After RC, GEE modeling showed physical function scores decreasing 5/100 points by 6 mo, and subsequently stabilizing or returning to baseline. By 12 mo, social function improved by 10/100 points among continent diversions, while remaining stable among ileal conduits. Global quality of life exceeded baseline scores by 6 mo. Sexual function scores were low before RC, with limited recovery. Psychosocial domains were stable or improved, except for 10/100-point worsening of body image among ileal conduits.
CONCLUSIONS: RC patients reported favorable HRQOL recovery within 24 mo in most areas other than body image (ileal conduits) and sexual function (both). Importantly, large measurable decreases in scores were not reported by 3 mo after RC. These contemporary outcomes and the excellent locoregional control provided by RC further support it as the gold standard therapy for high-risk bladder cancer. PATIENT
SUMMARY: We review quality of life in the 24 mo following radical cystectomy. Large decreases in health-related quality of life were not reported, with most areas returning to, or exceeding, baseline, except for sexual function and body image.
Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Patient-reported outcomes; Quality of life; Radical cystectomy

Mesh:

Year:  2021        PMID: 34629182      PMCID: PMC8891075          DOI: 10.1016/j.eururo.2021.09.018

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  37 in total

1.  The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life.

Authors:  M A Sprangers; A te Velde; N K Aaronson
Journal:  Eur J Cancer       Date:  1999-02       Impact factor: 9.162

2.  Quality of life in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy.

Authors:  Ismo Laitinen; Juhani Sand; Pipsa Peromaa; Isto Nordback; Johanna Laukkarinen
Journal:  Pancreatology       Date:  2017-02-24       Impact factor: 3.996

Review 3.  Quality of Life After Radical Cystectomy.

Authors:  Mark D Tyson; Daniel A Barocas
Journal:  Urol Clin North Am       Date:  2018-02-21       Impact factor: 2.241

4.  Validation of a decisional conflict scale.

Authors:  A M O'Connor
Journal:  Med Decis Making       Date:  1995 Jan-Mar       Impact factor: 2.583

5.  Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer.

Authors:  S Singer; C Ziegler; T Schwalenberg; A Hinz; H Götze; T Schulte
Journal:  Support Care Cancer       Date:  2012-12-14       Impact factor: 3.603

Review 6.  Systematic review and meta-analysis of non RCT's on health related quality of life after radical cystectomy using validated questionnaires: Better results with orthotopic neobladder versus ileal conduit.

Authors:  M A Cerruto; C D'Elia; S Siracusano; X Gedeshi; A Mariotto; M Iafrate; M Niero; C Lonardi; P Bassi; E Belgrano; C Imbimbo; M Racioppi; R Talamini; S Ciciliato; L Toffoli; M Rizzo; F Visalli; P Verze; W Artibani
Journal:  Eur J Surg Oncol       Date:  2015-11-09       Impact factor: 4.424

7.  Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.

Authors:  Bernard H Bochner; Michael W Kattan; Kinjal C Vora
Journal:  J Clin Oncol       Date:  2006-07-24       Impact factor: 44.544

Review 8.  A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer.

Authors:  Linda S Yang; Bernard L Shan; Leonard L Shan; Peter Chin; Spencer Murray; Nariman Ahmadi; Akshat Saxena
Journal:  Surg Oncol       Date:  2016-06-07       Impact factor: 3.279

9.  Development and validation of the functional assessment of chronic illness therapy treatment satisfaction (FACIT TS) measures.

Authors:  John D Peipert; Jennifer L Beaumont; Rita Bode; Dave Cella; Sofia F Garcia; Elizabeth A Hahn
Journal:  Qual Life Res       Date:  2013-09-24       Impact factor: 4.147

10.  Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.

Authors:  James W F Catto; Amy Downing; Samantha Mason; Penny Wright; Kate Absolom; Sarah Bottomley; Luke Hounsome; Syed Hussain; Mohini Varughese; Caroline Raw; Phil Kelly; Adam W Glaser
Journal:  Eur Urol       Date:  2021-02-10       Impact factor: 20.096

View more
  1 in total

1.  HRQOL after radical cystectomy.

Authors:  Maria Chiara Masone
Journal:  Nat Rev Urol       Date:  2021-12       Impact factor: 14.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.